(PFE) Pfizer - Ratings and Ratios

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical leader specializing in the discovery, development, and distribution of innovative medicines and vaccines. The company operates across multiple therapeutic areas, including cardiovascular and migraine treatments, infectious diseases, and cutting-edge solutions for COVID-19 prevention and treatment. Its product portfolio includes established brands such as Comirnaty (COVID-19 vaccine) and Paxlovid (COVID-19 oral treatment), as well as a robust pipeline of mRNA and antiviral products. Pfizer also maintains a strong presence in biosimilars, offering cost-effective alternatives for chronic immune and inflammatory diseases under brands like Xeljanz and Enbrel.

Additionally, Pfizer provides sterile injectable and anti-infective medicines, such as Zithromax and Medrol, catering to critical healthcare needs. The company’s oncology portfolio includes therapies like Ibrance, Xtandi, and Inlyta, targeting various cancers. Pfizer also addresses rare diseases, such as amyloidosis and hemophilia, with treatments like Vyndaqel and BeneFIX. Beyond its core business, the company engages in contract manufacturing and collaborates with major industry players, including BioNTech and Bristol-Myers Squibb, to advance medical innovation. Founded in 1849, Pfizer is headquartered in New York and serves a diverse customer base, including wholesalers, hospitals, and government agencies. Its market cap exceeds $127 billion, reflecting its financial stability and global influence.

3-Month Forecast (Technical & Fundamental Outlook): - Technical Data: The stock is currently trading below its SMA 20 (23.72) and SMA 50 (25.11), indicating bearish momentum. Support levels are absent in the provided data, while resistance levels range from 23.9 to 28.1. With an ATR of 0.70, price fluctuations are moderate. - Fundamental Data: A forward P/E of 7.65 suggests undervaluation potential, supported by a P/B ratio of 1.45. However, the RoE of 9.09 indicates modest profitability. - Forecast: Expect sideways to downward movement in the near term, with potential resistance at 23.9 and 25.7. A breakout above 25.7 could signal a reversal, but downside risks remain due to the stock trading below key moving averages. Fundamental strength may offset technical weakness if the company announces positive clinical trial results or strategic initiatives.